URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
UroGen Pharma Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$34.15−0.41 (-1.19%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
UroGen Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Market Cap | $1.67B | $166.30M |
| Enterprise Value | $1.75B | $87.12M |
| PS Ratio | 8.84 | 3.60 |
Enterprise value
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| EV / Sales | 9.27 | 2.43 |
Income (trailing twelve months)
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Revenue | $188.73M | $57.94M |
| Gross Profit | $171.46M | $90.47M |
| Operating Income | -$66.65M | -$21.49M |
| Pretax Income | -$98.11M | -$14.72M |
| Net Income | -$97.64M | -$22.46M |
| EBITDA | -$66.30M | -$17.14M |
| EPS (Diluted) | -$1.98 | -$0.83 |
Margins
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Gross Margin | 90.8% | 52.3% |
| Operating Margin | -35.3% | -44.5% |
| Pretax Margin | -52.0% | -13.0% |
| Profit Margin | -51.7% | -39.2% |
| EBITDA Margin | -35.1% | -31.3% |
| FCF Margin | -84.3% | -8.85% |
Returns
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | -42.3% | -41.0% |
| Return on Capital Employed (ROCE) | -35.0% | -38.0% |
Growth
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 100.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 19.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 56.2% | 6.42% |
Balance sheet
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $108.00M | $62.64M |
| Total Debt | $188.73M | $120.13M |
| Net Cash (Debt) | -$80.73M | $15.77M |
| Net Cash Per Share | -$1.65 | $0.66 |
| Equity (Book Value) | -$132.40M | $48.61M |
| Book Value Per Share | -$2.71 | $1.36 |
| Tangible Book Value | -$132.40M | $23.01M |
| Working Capital | $173.51M | $75.09M |
Financial position
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Current Ratio | 3.80 | 3.30 |
| Quick Ratio | 3.18 | 2.39 |
Cash flow (trailing twelve months)
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$158.92M | -$12.39M |
| Capital Expenditures | -$218.00K | -$1.07M |
| Free Cash Flow | -$159.14M | -$20.34M |
| FCF Per Share | -$3.26 | -$0.42 |
Efficiency
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.82 | 0.38 |
| Inventory Turnover | 1.09 | 2.67 |
| Revenue Per Employee | $648.57K | $398.96K |
| Profits Per Employee | -$335.52K | -$705.27K |
| Employee Count | 291 | 74 |
Dividends and yields
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Earnings Yield | -5.85% | -22.8% |
| FCF Yield | -9.53% | -9.02% |
Shares
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 48,880,600 | 58,139,000 |
| Shares Change (YoY) | 4.70% | 11.1% |
| Shares Change (QoQ) | 0.33% | 0.54% |
| Float | 46,168,100 | 49,154,900 |
| Shares Held by Insiders | 5.55% | 11.6% |
| Shares Held by Institutions | 86.8% | 59.4% |
Taxes
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Income Tax | -$472.00K | $89.00K |
Scores
| Measure | UroGen Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -2.23 | -0.27 |
| Piotroski F-Score | 0 | 4 |
| Beneish M-Score | -1.42 | -2.62 |
Calculated by StockData from UroGen Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.